|
gptkbp:instance_of
|
gptkb:character
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Bioverativ
|
|
gptkbp:activities
|
replaces deficient factor IX
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
with sterile water for injection
|
|
gptkbp:clinical_trial
|
Phase III
long-term prophylaxis
BAX 326-001
BAX 326-002
BAX 326-003
on-demand treatment
|
|
gptkbp:contraindication
|
hypersensitivity to components
active bleeding disorders
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:education
|
storage instructions
importance of adherence
proper injection technique
when to seek medical help
recognition of bleeding symptoms
|
|
gptkbp:effective_date
|
gptkb:2014
FDA approved
|
|
gptkbp:formulation
|
lyophilized powder
|
|
gptkbp:frequency
|
once every 7 to 14 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alprolix
|
|
gptkbp:indication
|
prophylaxis of bleeding episodes
|
|
gptkbp:ingredients
|
gptkb:eftrenonacog_alfa
|
|
gptkbp:is_monitored_by
|
factor IX levels
bleeding episodes
|
|
gptkbp:is_used_for
|
gptkb:hemophilia_B
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:manufacturer
|
gptkb:Baxter_International
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Japan
gptkb:North_America
|
|
gptkbp:pharmacokinetics
|
extended half-life
|
|
gptkbp:population
|
pediatric patients
adult patients
|
|
gptkbp:price
|
high-cost medication
|
|
gptkbp:regulatory_compliance
|
gptkb:Health_Canada
gptkb:European_Medicines_Agency
|
|
gptkbp:scholarships
|
Alprolix Patient Support Program
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
injection site reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target_audience
|
patients with hemophilia B
|
|
gptkbp:traded_on
|
gptkb:Alprolix
|